Genomik Design Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-05-2024
- Paid Up Capital ₹ 1.00 M
as on 21-05-2024
- Company Age 21 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
About Genomik Design Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Venkata Massireddigari, Venkata Boilla, and Enkemi Mutyala serve as directors at the Company.
- CIN/LLPIN
U24239TG2003PTC040246
- Company No.
040246
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2003
- Date of AGM
21 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Genomik Design Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Massireddigari  | Director | 02-Jun-2004 | Current |
| Venkata Boilla | Director | 27-Jun-2011 | Current |
| Enkemi Mutyala | Director | 27-Jun-2011 | Current |
Financial Performance of Genomik Design Pharmaceuticals.
Genomik Design Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Genomik Design Pharmaceuticals?
In 2017, Genomik Design Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rational Labs Private LimitedActive 20 years 11 monthsVenkata Boilla and Enkemi Mutyala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genomik Design Pharmaceuticals?
Unlock and access historical data on people associated with Genomik Design Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genomik Design Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genomik Design Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
